Alexion
NEWS
John Orloff and Brian Goff spoke with BioSpace about Alexion and new trends and developments the company is reporting.
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
Whenever drug companies come under criticism for the cost of their drugs, one of the defenses touted is that only about one in 10 drugs make it to market. As a broad figure, that’s probably about right, although at least one report ranks it higher, while another provides a bit more nuance.
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
The median salaries for Alexion employees increased to nearly $224,000 in 2018. The previous year the median salary was $167,000.
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
Alexion Pharmaceuticals announced two big collaboration partnerships today. First, Alexion, headquartered in Boston, and Affibody AB, located in Solna, Sweden, signed a partnership deal to co-develop ABY-039 for Immunoglobulin G (IgG)-mediated autoimmune diseases.
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
With Boston and the surrounding area being one of the centers of the pharmaceutical world, it should come as no surprise that some of the top-selling medications are based in the Bay State.
JOBS
IN THE PRESS